Trillium Therapeutics (Trillium Therapeutics) Additional Paid-In Capital : $41.41 Mil(As of Sep. 2021)

View and export this data going back to 2009. Start your Free Trial

What is Trillium Therapeutics Additional Paid-In Capital?

Trillium Therapeutics's quarterly additional paid-in capital declined from Mar. 2021 ($46.16 Mil) to Jun. 2021 ($40.41 Mil) but then increased from Jun. 2021 ($40.41 Mil) to Sep. 2021 ($41.41 Mil).

Trillium Therapeutics's annual additional paid-in capital increased from Dec. 2018 ($21.04 Mil) to Dec. 2019 ($23.07 Mil) and increased from Dec. 2019 ($23.07 Mil) to Dec. 2020 ($38.63 Mil).

Trillium Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Trillium Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trillium Therapeutics Additional Paid-In Capital Chart

Trillium Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Additional Paid-In Capital

Get a 7-Day Free Trial

9.19

12.60

21.04

23.07

38.63

Trillium Therapeutics Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21
Additional Paid-In Capital	Get a 7-Day Free Trial															41.98	38.63	46.16	40.41	41.41

Trillium Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Trillium Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Trillium Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Trillium Therapeutics (Trillium Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trillium Therapeutics Inc (NAS:TRIL) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 CambridgePark Drive, Suite 510, Cambridge, MA, USA, 02140

Website

https://www.trilliumtherapeutics.com

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.